Aura Biosciences to Participate in Upcoming Investor Conferences

August 28, 2024

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:

- **Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024.** Members of Aura's senior management team will participate in one-on-one investor meetings.
- **H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024.**

Members of Aura's senior management team will participate in one-on-one investor meetings. A virtual presentation by Elisabet de los Pinos, PhD, Chief Executive Officer, will be available on Monday, September 9, 2024 at 7:00 am ET at https://journey.ct.events.

The presentation at the H.C. Wainwright conference will also be available at such time on the "Investors & Media" page under the " Events & Presentations" section of the Company's website at https://ir.aurabiosciences.com/events-and-presentations, where it will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. We are evaluating the safety and efficacy of bel-sar as a potential vision-sparing therapy in an ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early-stage choroidal melanoma. Bel-sar is also being evaluated in additional solid cancers, including bladder cancer. Our mission is to develop vision and organ-sparing therapies to improve patient outcomes in cancer. Aura is headquartered in Boston, MA. For more information, visit aurabiosciences.com. Visit us @AuraBiosciences and on LinkedIn.

Investor and Media Contact:

Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com

Source: Aura Biosciences, Inc.